2D Speckle-tracking Echocardiography in Chemotherapy-induced Cardiomyopathy With Cardiovascular Risk Factors

The Role of 2D Speckle-tracking Echocardiography in Diagnosis Chemotherapy-induced Cardiomyopathy in Breast Cancer Patients With High Cardiovascular Risk Factors

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04547465

Enrollment

300

Registered

2020-09-14

Start date

2020-09-15

Completion date

2023-12-30

Last updated

2023-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Cardiomyopathy Due to Drug, Cardiovascular Risk Factor

Brief summary

The aims of this study is to evaluate the role of 2D speckle-tracking echocardiography in diagnosis chemotherapy related left ventricular dysfunction in breast cancer patients with cardiovascular risks

Detailed description

Chemotherapy induced cardiomyopathy is a serious adverse effect of anticancer treatments with poor long-term prognosis. In addition to the cumulative dose of anthracycline and trastuzumab, cardiovascular risks have been proven to be the second hit when dealing with chemotherapy related cardiomyopathy in breast cancer patients. Speckle-tracking echocardiography have had robust evidence in diagnosis the early stage of left ventricular dysfunction in various types of cancer treated by cardiotoxicity drugs. However, data is still lacking regarding the role of speckle-tracking echocardiography in breast cancer patients with cardiovascular risk

Interventions

DIAGNOSTIC_TESTEchocardiography

2D Speckle-tracking echocardiography

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Breast cancer patients treated by anthracycline and/or trastuzumab * Have at least one of these cardiovascular risks: age \> 60, hypertension, atrial fibrillation, diabetes mellitus, dyslipidemia, chronic kidney disease, obesity, family history of cardiovascular diseases.

Exclusion criteria

* Left ventricular ejection fraction \< 50% before chemotherapy * Chronic heart failure with NYHA functional class \>= II * Significant valvular stenosis/regurgitation * Acute heart failure due to acute coronary syndrome during follow-up

Design outcomes

Primary

Measure	Time frame	Description
The incidence of chemotherapy induced cardiomyopathy in breast cancer patients with cardiovascular risk	two year follow-up	the incidence
The kinetics of left ventricular global longitudinal strain (LV-GLS) in breast cancer patients treated by anthracycline and/or trastuzumab	two year follow-up	global longitudinal strain (percentage)
The cut-off value of global longitudinal strain (GLS) to predict chemotherapy induced cardiomyopathy in breast cancer patients treated by anthracycline and/or trastuzumab	two year follow-up	global longitudinal strain (percentage)
The kinetics of right ventricular longitudinal strain (RV-GLS and RV-FWLS) in breast cancer patients treated by anthracycline and/or trastuzumab	two year follow-up	longitudinal strain (percentage)
The kinetics of left atrial longitudinal strain (LASr, LAScd, LASct) in breast cancer patients treated by anthracycline and/or trastuzumab	two year follow-up	longitudinal strain (percentage)

Countries

Vietnam

Contacts

Primary ContactNhat M. Giang, M.D

minhnhat210189@gmail.com+84919963999

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026